Aster DM Quality Care Ltd Q4 FY2022 Concall Summary

Key Takeaways

• India drove the quarter, GCC normalized: India revenue grew 26% YoY and EBITDA more than doubled, while GCC posted 11% YoY growth as Dubai returned toward normalcy.
• Margins improved sharply, but Q4 pharmacy benefit was lumpy: Consolidated EBITDA rose 40% YoY, yet GCC pharmacy margins were flattered by a ~Rs. 40 crores annual purchase benefit that landed disproportionately in Q4.
• The digital and omnichannel build is now live: The "One Aster" app launched in controlled release, an e-pharmacy app is days away, and management expects the omnichannel ecosystem to be a reality within 6 months.
• Corporate restructuring and Saudi monetization are active, unresolved processes: A Board subcommittee is meeting frequently on GCC restructuring, and Saudi hospital due diligence is nearly concluded, but no timelines have been set for either.
• What to watch next quarter: Whether the Saudi hospital deal and GCC restructuring produce concrete updates, the pace of India margin expansion toward the promised high-teens, and how much the Ramadan/Eid holiday period depressed GCC Q1 FY23 volumes.

India Business: The Margin Inflection Story

• Hospitals delivered the step-change: Q4 India revenue of Rs. 607 crores, up 26% YoY, with EBITDA more than doubling to Rs. 79 crores; full-year India EBITDA margin reached 15%, up from 9% a year ago.
• Price increases already taken: Majority of hospitals in the Kerala and Karnataka clusters took price increases of 5% to 15% in Q1 FY23 or late Q4, providing a tailwind for the coming year.
• New hospital drag is manageable: Only the Whitefield project comes onstream in FY23; the Karnataka and Kerala cluster assets are over 3 years old and can absorb new-unit losses, with the consolidated India margin drag expected at less than 100 bps.
• FY23 margin target is explicit: Management expects India hospital margins (excluding new hospitals) in the higher teens, upwards of 19%, with consolidated India margins continuing to improve from present annual levels.
• Asset-light bed addition scales without capex: The O&M model added 140 beds at Aster Areekode Mother Hospital in Kerala; management targets 500–1,000 O&M beds in FY23, largely in Kerala, Karnataka, Andhra Pradesh, and Telangana, with almost nil capital deployed.

Dr. Azad Moopen: "We hope that we'll be able to have significant number of hospitals in India, in the geographies that we operate, and this can add to our number of beds to a great extent without capex being brought in."

GCC: Normalization with Margin Nuance

• Hospitals led GCC growth: Q4 GCC hospital revenue of Rs. 944 crores, up 14% YoY, driven by better performance across the portfolio including Saudi; occupancy reached 66%, a level management says continued even after COVID PCR testing revenue faded and has persisted into the next quarter.
• Pharmacy margins need a full-year lens: Q4 pharmacy EBITDA margin jumped to 18.5% from 11.9% YoY, but ~Rs. 40 crores of the improvement came from an annual OEM purchase benefit that crystallized in Q4 because volume targets were finalized then. Management urged investors to look at full-year margins, not the Q4 spike, and expects the benefit to be sustainable on an annual basis.
• Non-pharma mix shift supports pharmacy structurally: Non-pharma share moved from 25% to 30% of pharmacy mix, carrying higher margins through own products and white-label goods.
• Clinics face a PCR hangover: RT-PCR contributed ~33% of clinic revenue in FY22; with that revenue gone, clinic margins will drop in Q1 and Q2 FY23, though core footfall is normalizing to pre-COVID levels as respiratory, pediatric, and ENT cases return.
• Insurance pressure caps ARPOB upside: Management does not expect significant ARPOB increases in GCC, citing ongoing pressure from insurance companies; any revenue uplift will come from occupancy gains and a case-mix shift toward tertiary care (neurosurgery, oncology) rather than price.
• Saudi turnaround strengthens negotiating position: The Saudi hospital restored double-digit margins over the last 5 months through new business tenders won and complete renegotiation of insurance contracts on 5-year terms, attracting interest from multiple prospects for the planned divestiture.

Amitabh Johri: "In this particular quarter that has gone by, we have had almost Rs. 40-odd crores of purchase benefit, which has come in, which is mainly towards the purchases that we have made during the year because of post-COVID."

Digital & Omnichannel: From Build to Revenue

• The ecosystem is going live now: The "One Aster" app launched in controlled release in April 2022, attracting over 10,000 users and 2,000-plus registrations with only virtual consultation enabled so far. An e-pharmacy app will launch within days, and management expects the full omnichannel ecosystem connecting hospitals, clinics, pharmacies, home care, and virtual consultation to be a reality within 6 months across GCC and India.
• Early monetization signals are tangible: WhatsApp-based pharmacy ordering, without a dedicated app, already generated almost Rs. 50 crores in revenue, demonstrating latent demand from the captive patient base. A GP-to-hospital referral management program generated Rs. 18 crores in 2.5 quarters from a limited pilot, and a chronic disease management platform pulling HIS data generated Rs. 10 crores in 1.5 quarters.
• Digital CRM and data lake are scaling: The CRM initiative, piloted in obstetrics & gynecology and orthopedics, is now being made a mainstream revenue initiative. A cross-vertical data lake project has begun with technology partners, with use cases planned across marketing, finance, clinical, and operations.
• Total digital spend is ~Rs. 175 crores: Rs. 56 crores already spent; the balance will flow over the next two years, covering development, marketing, and organizational setup across India and GCC.
• India omnichannel pilot targeted for H2 FY23: After the UAE launch, management plans to replicate the omnichannel care model in India, starting with a pilot within the Kerala cluster in the second half of FY23.

Dr. Azad Moopen: "We think that it will be a force multiplier, which will have a significant impact on our revenues as well as our patient comfort."

Corporate Actions: Restructuring and Saudi Monetization

• GCC restructuring is a Board priority with no timeline: A subcommittee of independent directors is meeting frequently, but management stated the committee has not set any timelines and declined to comment further, saying only that more clarity is expected by the next investor call.
• Saudi hospital divestiture is advancing slowly: Due diligence is almost concluded, and the recent operational turnaround has attracted interest from additional prospects. Management is exploring options: revisiting valuation given the improved performance, partial monetization, or bringing in a Saudi partner to fund a low-capex rollout of pharmacies, clinics, and labs. A stronger update is expected next quarter.
• Sequencing between Saudi and GCC restructuring is unresolved: Saudi may proceed first, but both could happen simultaneously; the restructuring sequence affects which entity handles the Saudi sale. Management expects more clarity on both processes without much delay.

Alisha Moopen: "We do want to look at it quite strategically because Saudi is a big market for us. We have been there for a while, and we've been seeing that there is a very big difference post-COVID in that way the reforms have happened within health care... we do not want to take a very rush step when we see a turnaround on the business as well."

Expansion Pipeline: Beds, Labs, Pharmacies, and New Markets

• GCC capacity is expanding now: The 101-bed Aster Hospital Sharjah commenced operations in April 2022, and Aster Hospital Muscat is expected to commission in the next 1–2 months, taking GCC capacity to 1,406 beds.
• India bed capacity target is 4,300–4,400 by FY23 end: Approximately 400 beds will be added, with potential upside from brownfield O&M projects.
• Aster Labs is scaling rapidly: The lab network entered 4 new states (Maharashtra, Tamil Nadu, Andhra Pradesh, Telangana) and plans to reach 38 labs and over 400 patient experience centers by FY23 end. A home-phlebotomy lab service is also launching in the UAE.
• Aster Pharmacy targets 300 stores by FY23 end: The 100th store opened in Kochi, with 131 operational as of March 2022; a franchise model is being explored, along with expansion feasibility in Jordan and Bahrain.
• Tamil Nadu MoU signed for Rs. 500 crores: Investment over 3 years in hospitals, pharmacies, and laboratories, using an asset-light model where a partner constructs the hospital building; low-cost labs and pharmacies will roll out even before the hospital starts.
• Wellness clinics are a new format: Clinics focused on functional medicine, cosmetics, aesthetics, IV drip therapy, dental, and mental health are being set up, representing a new service line beyond traditional acute care.

Guidance & Commitments

Key Metrics